Susquehanna International Group’s VYNE Therapeutics VYNE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $95.4K | Buy |
57,814
+52
| +0.1% | +$86 | ﹤0.01% | 5905 |
|
|
2025
Q1 | $91.3K | Sell |
57,762
-13,070
| -18% | -$20.7K | ﹤0.01% | 5882 |
|
|
2024
Q4 | $237K | Buy |
70,832
+10,476
| +17% | +$35.1K | ﹤0.01% | 5058 |
|
|
2024
Q3 | $113K | Buy |
60,356
+33
| +0.1% | +$62 | ﹤0.01% | 5078 |
|
|
2024
Q2 | $119K | Hold |
60,323
| – | – | ﹤0.01% | 5031 |
|
|
2024
Q1 | $185K | Hold |
60,323
| – | – | ﹤0.01% | 4724 |
|
|
2023
Q4 | $141K | Sell |
60,323
-15,448
| -20% | -$36K | ﹤0.01% | 5190 |
|
|
2023
Q3 | $303K | Sell |
75,771
-609
| -0.8% | -$2.44K | ﹤0.01% | 4025 |
|
|
2023
Q2 | $310K | Buy |
76,380
+58,368
| +324% | +$237K | ﹤0.01% | 4190 |
|
|
2023
Q1 | $55.5K | Buy |
18,012
+17,096
| +1,866% | +$52.7K | ﹤0.01% | 5417 |
|
|
2022
Q4 | $2.47K | Sell |
916
-469
| -34% | -$1.27K | ﹤0.01% | 5618 |
|
|
2022
Q3 | $6K | Buy |
+1,385
| New | +$6K | ﹤0.01% | 5880 |
|
|
2022
Q2 | – | Sell |
-568
| Closed | -$7K | – | 6749 |
|
|
2022
Q1 | $7K | Sell |
568
-1,950
| -77% | -$24K | ﹤0.01% | 5586 |
|
|
2021
Q4 | $46K | Buy |
2,518
+1,724
| +217% | +$31.5K | ﹤0.01% | 5489 |
|
|
2021
Q3 | $20K | Sell |
794
-1,850
| -70% | -$46.6K | ﹤0.01% | 5190 |
|
|
2021
Q2 | $167K | Buy |
+2,644
| New | +$167K | ﹤0.01% | 4927 |
|
|
2021
Q1 | – | Sell |
-472
| Closed | -$54K | – | 5810 |
|
|
2020
Q4 | $54K | Buy |
472
+92
| +24% | +$10.5K | ﹤0.01% | 4610 |
|
|
2020
Q3 | $45K | Buy |
+380
| New | +$45K | ﹤0.01% | 4235 |
|
|
2020
Q2 | – | Sell |
-1,003
| Closed | -$193K | – | 5006 |
|
|
2020
Q1 | $193K | Buy |
+1,003
| New | +$193K | ﹤0.01% | 3809 |
|